Core Viewpoint - Tian Tan Biological Products Co., Ltd. has received approval from the National Medical Products Administration to conduct clinical trials for "human fibrinogen" [1] Company Summary - Tian Tan Kunming, a subsidiary of Tian Tan Biological Products, is the entity that obtained the clinical trial approval [1]

Core Viewpoint - TianTan Biological (600161) has received approval from the National Medical Products Administration for clinical trials of "human fibrinogen" to treat congenital fibrinogen deficiency or lack [1] Company Summary - TianTan Kunming, a subsidiary of TianTan Biological, has been granted a Clinical Trial Approval Notice for the drug "human fibrinogen" [1] - The drug is indicated for conditions such as congenital fibrinogen deficiency or lack [1]

Core Viewpoint - Beijing Tiantan Biological Products Co., Ltd. has received approval from the National Medical Products Administration to conduct clinical trials for "human fibrinogen" [1] Company Summary - The product is classified as a therapeutic biological product with a specification of 0.5g (25ml) per bottle and is in injectable form [1] - The research and development investment for this product amounts to 5.9925 million yuan [1] - Indications for the product include congenital and acquired fibrinogen deficiency [1] Industry Summary - Several domestic companies produce similar products, while the international market includes competitors such as CSL Behring and Octapharma [1] - The product must complete multiple approval processes before it can be marketed, indicating uncertainty in drug development [1]

Group 1 - The company announced the resignation of its Chief Compliance Officer and General Counsel, Ms. Ci Xiang, who submitted her resignation report to the board [1] - Ms. Ci Xiang will continue to serve on the board of the company's subsidiary, China National Pharmaceutical Group Xi'an Biological Pharmaceutical Co., Ltd. (Tian Tan Xi'an), until a new director is elected [1] - The company will expedite the appointment of a new director for Tian Tan Xi'an [1] Group 2 - As of the announcement date, Ms. Ci Xiang directly holds 24,000 shares of the company, accounting for 0.0012% of the total shareholding [2] - Ms. Ci Xiang will continue to adhere to her commitment not to reduce her shareholding within the statutory period [2] - The resignation will not affect the normal operations of the company, and the board expressed gratitude for Ms. Ci Xiang's contributions over the years [2]

Core Viewpoint - Tian Tan Biological announced the resignation of Ms. Ci Xiang, which will take effect upon delivery to the company's board of directors. [1] Group 1 - Following Ms. Ci Xiang's resignation, the board of directors of Tian Tan Xi'an, a subsidiary of the company, will have fewer members than the legal requirement. [1] - Ms. Ci Xiang will continue to fulfill her duties as a director of Tian Tan Xi'an until a new director is elected. [1]

Group 1 - The company TianTan Bio (SH 600161) announced the resignation of its General Counsel and Chief Compliance Officer, Ci Xiang, effective immediately upon delivery of her resignation to the board [1] - Following Ci Xiang's departure, the board of directors of the company's subsidiary, China National Pharmaceutical Group Xi'an Biological Pharmaceutical Co., Ltd., fell below the legal number of members, prompting Ci Xiang to continue serving as a director until a new director is elected [1] - For the first half of 2025, the company's revenue composition shows that the biopharmaceutical industry accounts for 99.68% of total revenue, while other businesses contribute 0.32% [1] - As of the report date, the market capitalization of TianTan Bio is 38 billion yuan [1] Group 2 - The competitive landscape in the beverage industry is highlighted by a significant market share decline for Yi Bao, which dropped nearly 5 percentage points following the launch of the Farmer Green Bottle [1]

证券代码：600161 证券简称：天坛生物 公告编号：2025-047 北京天坛生物制品股份有限公司高级管理人员离任公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、离任对公司的影响 根据《中华人民共和国公司法》和《公司章程》等相关规定，慈翔女士的辞 职报告自送达公司董事会之日起生效；因慈翔女士离任后，公司控股子公司国药 集团西安生物制药有限公司（以下简称"天坛西安"）董事会成员低于法定人数， 慈翔女士将继续履行天坛西安董事职责，期限至天坛西安选举新任董事之日止。 公司将尽快完成天坛西安新任董事委派工作。 截至本公告披露日，慈翔女士直接持有本公司 24,000 股股份，占公司总股 比的 0.0012%。慈翔女士将继续遵守其增持公司股票时作出的在法定期限内不减 持所持公司股份的承诺（见公司于 2023 年 8 月 30 日披露的《关于董事、监事、 高级管理人员增持股份计划公告》）。 特此公告。 北京天坛生物制品股份有限公司（以下简称"公司"）董事会于近日收到公 司总法律顾问、首席合规官慈翔女士递交的书面辞职报告。现将有关 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 表决结果：9票同意，0票反对，0票弃权。 2024年及2025年1-6月，上生公司营业收入分别为1,197万元、808万元，仅占公司营业收入的0.2%、 0.26%；2024年及2025年1-6月，上生公司净利润为23万元、-72万元，仅占公司净利润的 0.01%、-0.08%。（上述2025年1-6月数据未经审计） 本次董事会审议事项仅为上生公司处置项目立项，具体处置方案尚未确定，后续公司尚需按照相关规定 完成审计、评估等工作，确定处置方案，履行董事会审批程序，并及时进行信息披露。上生公司处置项 目具体实施方案及审批尚存在不确定性，敬请投资者注意投资风险。 特此公告。 证券代码：600161 证券简称：天坛生物 公告编号：2025-046 北京天坛生物制品股份有限公司 第九届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司(以下简称"公司")第九届董事会第二十五次会议于2025年9月19日以电 子方式发出会议通知，于2 ...

证券代码：600161 证券简称：天坛生物 公告编号：2025-046 特此公告。 北京天坛生物制品股份有限公司 第九届董事会第二十五次会议决议公告 北京天坛生物制品股份有限公司(以下简称"公司")第九届董事会第二十五 次会议于 2025 年 9 月 19 日以电子方式发出会议通知，于 2025 年 9 月 26 日以通 讯表决方式召开。会议应参加表决董事九人，实际参加表决董事九人。会议符合 《公司法》及《公司章程》的有关规定，会议审议通过以下议案： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 审议通过《关于处置上海上生生物制品经营有限公司项目立项的议案》，同 意处置公司所属上海上生生物制品经营有限公司（以下简称"上生公司"）项目 立项。本议案经董事会战略与投资委员会事前认可。 表决结果：9 票同意，0 票反对，0 票弃权。 2024 年及 2025 年 1-6 月，上生公司营业收入分别为 1,197 万元、808 万元， 仅占公司营业收入的 0.2%、0.26%；2024 年及 2025 年 1-6 月，上生公司净利润 ...

截至发稿，天坛生物市值为376亿元。 每经头条（nbdtoutiao）——5年增长33倍，这类新险种卖爆了，身边很多人都需要，30多家险企蜂拥而 入⋯⋯ （记者 张喜威） 每经AI快讯，天坛生物（SH 600161，收盘价：19.02元）9月26日晚间发布公告称，公司第九届第二十 五次董事会会议于2025年9月26日以通讯表决方式召开。会议审议了《关于处置上海上生生物制品经营 有限公司项目立项的议案》等文件。 2025年1至6月份，天坛生物的营业收入构成为：生物制品行业占比99.68%，其他业务占比0.32%。 ...